DESTINE 2.0 on LVAD driveline infections, and an ESC consensus on lipid-lowering therapy in venous thromboembolism

Two new documents, both published 9 September. All three sweeps ran clean with no query failures: the topic-wide guideline search across all journals (32 hits), the society-acronym sweep, and the French-society sweep — which returned a confirmed zero again for 1–10 September. SFAR, SPILF, SRLF and Infectious Diseases Now have now published nothing in guideline form for ten days running.

1. DESTINE 2.0 — driveline infections in LVAD patients

Group · Published: The Driveline Expert STagINg and carE (DESTINE) study group. Artificial Organs, 9 September 2026 — published yesterday Bernhardt, Lauenroth, Mueller, Kaufmann, Homann, Socha, Schlöglhofer

Not one of the tracked societies, but an international expert group updating its own 2020 protocol, and squarely primary scope: mechanical circulatory support is cardiothoracic surgery, and driveline infection is where that overlaps with infectious disease.

The problem as stated:

Driveline infections (DLIs) remain the predominant device-specific complication in patients supported by left ventricular assist devices, serving as a major source of morbidity, recurrent hospitalization, and mortality. Despite their clinical impact, the prevention and early management of DLIs lack standardization, particularly within outpatient and home-based care environments.

What DESTINE 2.0 changes, and why — this is unusually frank about its predecessor’s failures:

• The original 2020 proposal’s early-stage subcategorisation was overly complex, and it lacked contemporary guidance on wound care — fixation, antiseptics, adjunctive therapies
• Streamlined five-stage system, consolidating the previous subcategories into “unambiguous, actionable clinical stages”
• Enhanced recommendations for driveline immobilisation, stage-stratified antiseptic selection, and skin barrier preservation
• Adjunctive therapies now included: cold atmospheric plasma and closed-incision negative pressure wound therapy
• Expanded guidance on modifiable patient-level risk factors, perioperative prophylaxis, showering safety, caregiver education, digital documentation, and stage-directed antibiotic therapy

Interpretation. This is the more useful of today’s two documents, and the reason is the part that sounds least impressive: the staging system was simplified because it was too complicated to use.

That is a real finding about guideline implementation, reported honestly by the group that got it wrong the first time. A staging system whose early stages subdivide into categories nobody can reliably distinguish does not produce consistent care — it produces disagreement dressed as classification. Collapsing them into five “unambiguous, actionable” stages is a downgrade in descriptive precision and an upgrade in everything that matters. Compare the SENTINEL appraisal of hospital sepsis guidelines sent yesterday: the recommendations that transmitted correctly across fourteen countries were the simple, time-anchored ones.

The outpatient framing is the other substantive shift. The stated gap is prevention and early management “particularly within outpatient and home-based care environments” — and the expanded guidance reflects it: showering safety, caregiver education, driveline fixation, digital documentation. This is a document about what happens in a patient’s bathroom, not in an operating theatre, and that is correct prioritisation. Driveline infections are acquired over months at home and present to hospital already established.

Two items deserve scepticism. Cold atmospheric plasma and closed-incision negative pressure wound therapy are adjunctive therapies with thin evidence in this specific indication — the abstract says the protocol “incorporates” them, not that they are recommended on strong evidence, and the document is explicitly expert recommendations rather than a graded guideline. No GRADE assessment is mentioned anywhere. Read the staging system and the wound-care basics as the substance; treat the adjuncts as options someone thought worth listing.

For the perioperative team, the line that matters is perioperative prophylaxis and stage-directed antibiotic therapy — an LVAD patient returning to theatre with a staged driveline infection now has a framework for what antibiotic decision the stage implies. That sits alongside the mechanical circulatory support upgrades in the 2026 ESC heart failure guidelines already in this archive: more patients on long-term support means more of this.

Access note: the abstract is deposited and was read in full. The five stages themselves — what distinguishes stage 2 from stage 3 — are not in the abstract and the full text was not reachable. The staging criteria are the operative content and need the paper.

Read the recommendations · PMID 42717402

2. ESC clinical consensus — lipid-lowering therapy in venous thromboembolism

Societies · Published: ESC Working Group on Aorta and Peripheral Vascular Diseases, ESC Working Group on Cardiovascular Pharmacotherapy, ESC Working Group on Pulmonary Circulation & Right Ventricular Function, and the European Society of Vascular Medicine. European Journal of Preventive Cardiology, 9 September 2026 — published yesterday Espinola-Klein, Heiss, Brodmann, Gary, Mazzolai, Bura-Rivière, Linnemann, Aboyans, Rodríguez Palomares, Klok, Drexel, Belch, Vrsalović, Schlager

ESC is a tracked society, so this counts — though it is a Working Group consensus statement rather than a guideline, and secondary scope (cardiology).

What it says:

• The aim is to summarise existing evidence on lipid-lowering therapy in primary and secondary prevention of venous thromboembolism — DVT and pulmonary embolism
• VTE shares common risk factors with atherosclerotic cardiovascular disease
• Anticoagulation remains the mainstay of VTE management
• “It may be appropriate to define LLT as risk modifier in primary prevention of VTE in populations at high cardiovascular risk”
• In patients who have had VTE, assessing cardiovascular risk factors including lipids is already part of routine cardiovascular care under existing ESC guidelines
• The statement “highlights the gaps in evidence and the need for large-scale studies directly investigating the role of LLT in secondary prevention of recurrent VTE”

Interpretation. Read the abstract carefully and this document is candid about being a map of a gap rather than a filling of one, which is worth respecting and worth saying plainly.

There is no new recommendation here. The strongest statement is that LLT “may be appropriate” as a risk modifier in primary prevention in people who are already at high cardiovascular risk — that is, in people who should be on a statin anyway for arterial disease. The secondary-prevention question — does lipid-lowering reduce recurrent VTE — is explicitly left open, with a call for large-scale studies. Four working groups across two societies have produced a statement whose operative conclusion is that the trials have not been done.

That is not a criticism of the document; it is the document’s own position, and a consensus statement that declines to recommend on absent evidence is behaving better than one that invents a recommendation. It is a criticism of how such statements get cited, though: the phrase “ESC consensus on lipid-lowering in VTE” will travel further than the content, and somebody will eventually start a statin for a pulmonary embolism on the strength of it.

The mechanistic premise — that VTE and ASCVD share risk factors — is real and the epidemiological overlap is well established. Whether statins reduce venous events has been asked before, most notably by JUPITER’s secondary analysis, and has never been settled by a trial designed to answer it. This statement is an accurate report of that position in 2026.

Relevance to this archive is limited and honest to state. Perioperative VTE prophylaxis, neuraxial timing around anticoagulants, and PE in the critically ill are all in scope; lipid-lowering for VTE risk modification is not a perioperative decision. It is recorded here because ESC is tracked and because the negative — no evidence, do not act yet — is the useful part.

Read the statement · PMID 42712221

---

Also seen and not written up: the AARC Clinical Practice Guideline on adult patients transitioning from hospital on oxygen (Respiratory Care, 9 September, DOI 10.1177/19433654261472990) — a properly GRADE-assessed guideline on long-term oxygen therapy at discharge, with one strong recommendation (disease management for newly prescribed LTOT, low certainty) and the rest conditional; domiciliary respiratory care rather than anaesthesia, intensive care or cardiothoracic surgery, so out of scope but noted for anyone whose ICU survivors go home on oxygen. Also an ASPAN modified e-Delphi on bedside decision-support strategies for PACU nursing clinical reasoning (10 of 14 strategies reaching consensus, including mentoring and shared decision-making) — about nursing education frameworks rather than clinical management. Out of scope: an Endocrine Society scientific statement on obesity medicines, EFP periodontal guidelines, ISTH haemophilia bleeding-rate reporting, DEGRO radiotherapy recommendations for Merkel cell carcinoma, an Austrian ÖGGH consensus on primary biliary cholangitis, and a Nature Medicine call for collaborators on validating generative AI. The two EJA items dated 9 September are the same correspondence replies noted yesterday.